IN BRIEF: EMV Capital portfolio company ProAxsis plans fundraise

EMV Capital PLC - life sciences focused investor - Portfolio company ProAxsis plans to raise ...

Alliance News 3 February, 2025 | 8:06PM
Email Form Facebook Twitter LinkedIn RSS

EMV Capital PLC - life sciences focused investor - Portfolio company ProAxsis plans to raise GBP800,000 via the issue of new shares. ProAxsis is a respiratory diagnostics company and a spin-out from Queens University Belfast. Proceeds will be divided as to GBP500,000 towards core business activities, and GBP300,000 towards advancing a COPD clinical study with Imperial College. In addition, ProAxsis says revenue rose 92% to GBP470,000 in 2024. EMV has a near 89% stake in ProAxsis which had a fair value of GBP8.0 million as at June 30, 2024.

Current stock price: 50.00 pence

12-month change: down 22%

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2025 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
EMV Capital PLC 48.50 GBX 0.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures